

Study	NCT ID	Completion Date	Population	Treatment duration	Participants,n	Interventions(mg)	Age,years	Male, n (%)	BMI, kg/m ²	T2D,n (%)
Jastreboff AM,2023	NCT04881760	2022.11	Overweigh/Obesity	48weeks	338	1-12;qw	48.2(12.7)	175 (51.8%)	37.3(5.7)	0
Shweta Urva,2022	NCT04143802	2020.12	T2D	12weeks	67	0.5-12;qw	58.4 (7.4)	35 (49%)	32.1(5.1)	72(100)
Julio Rosenstock,2023	NCT04867785	2022.10	T2D	36weeks	235	0.5-12;qw	56.2 (9.7)	125(44%)	35.0(6.3)	281(100)

Table 1. Baseline characteristics of participants in the included retatrutide trials. Age and BMI were reported in Mean±SD.